AVIR logo

AVIR Atea Pharmaceuticals, Inc.

NASDAQ · Biotechnology · Healthcare

$3.96
+0.03 (+0.76%)

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company a…

Market Cap: $318.00Mwww.ateapharma.com

Price

No data yet.

Social Signal Score

45
5d
—
30d
45
4 mentions
—
60d
45
4 mentions
—
90d
45
4 mentions
—
news: 4

Analyst Ratings

4 analysts
Holdconsensus
Strong Buy 0Buy 1Hold 2Sell 1Strong Sell 0
Avg price target$7+76.8%
Low $7Median $7High $7
Current Consensus

Revenue

$0.00
$0.00$64.06M$128.12M$192.18M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-1.73
$-1.89–$-1.55
2 analysts
FY2026
$-1.68
$-1.76–$-1.60
1 analysts
FY2027
$-1.36
$-1.60–$-1.12
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jean-Pierre Sommadossi
Sector
Healthcare
Industry
Biotechnology
Employees
55
Beta
0.28
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
1.59
www.ateapharma.com